Drug intelligence / Profile preview

Zuandol

Development stage: Unknown
Lead developer: GP Pharma
Modality: Small Molecules
Administration: Oral

Overview

Zuandol is a small molecule phosphodiesterase type 5 (PDE5) inhibitor developed by GP Pharma (GP-Pharm, S.A.) for the treatment of erectile dysfunction. The drug contains sildenafil citrate as its active ingredient, which works by selectively inhibiting the PDE5 enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. By maintaining elevated levels of cGMP, Zuandol promotes smooth muscle relaxation and vasodilation, facilitating an erection in the presence of sexual stimulation. It was approved in Spain in 2011 as a generic medication (EFG) and is available in oral tablet strengths of 50 mg and 100 mg.

Brand names: Zuandol
Other names: sildenafilsildenafil citrate

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on Zuandol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zuandol.

Explore the full profile